OMEROS CORP

OMER ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Revenue $73.8M $111.8M
Cost of Revenue $902.0K $865.0K
Gross Profit $72.9M $110.9M
Gross Margin 98.8% 99.2%
Operating Expenses
Research & Development $81.3M $119.5M $114.9M $112.7M $118.8M $107.6M $106.3M
SG&A Expense $41.5M $47.4M $49.7M $50.7M $54.8M $49.3M $39.7M
Operating Income $-122.8M $-167.0M $-164.5M $-163.4M $-173.6M $-156.9M $-146.0M
Operating Margin -212.6% -130.6%
Interest Expense $30.8M $22.7M $19.7M $26.8M $22.7M
Pretax Income $-2.8M $-180.3M $-174.9M $-182.0M $-191.5M $-196.4M $-167.1M
Income Tax Expense $2.0M $2.3M $0 $0 $0 $-23.3M $-19.8M
Net Income $-3.4M $-156.8M $-117.8M $47.4M $194.2M $-138.1M $-84.5M
Net Margin -187.0% -75.6%
EPS (Basic) $-0.05 $-2.70 $-1.88 $0.76 $3.12 $-2.41 $-1.71
EPS (Diluted) $-0.05 $-2.70 $-1.88 $0.76 $3.12 $-2.41 $-1.71
Shares Outstanding (Basic) 72.0M 63.5M 58.2M 62.7M 62.7M 62.3M 57.2M 49.5M
Shares Outstanding (Diluted) 72.0M 63.5M 58.2M 62.7M 62.7M 62.3M 57.2M 49.5M
Dividends Per Share
← Newer Page 1 of 3 Older →
Benjamin Graham

The stock investor is neither right or wrong because others agreed or disagreed with him; he is right because his facts and analysis are right.